Related Experiment Video
Updated: Aug 9, 2025
06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
5.8K
Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune
Dagmar Riemann1, Steffi Turzer1, Georgi Ganchev2
1Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, 06112 Halle, Germany.
Biomolecules
|February 25, 2023
Summary
This study reveals that specific blood immune cell signatures, including neutrophil-to-lymphocyte ratio and monocyte/dendritic cell levels, can predict outcomes for small cell lung cancer (SCLC) patients. These markers may also help understand SCLC
Area of Science:
- Immunology
- Oncology
- Flow Cytometry
Background:
- Small cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options.
- Immune checkpoint inhibitors combined with chemotherapy are used for SCLC treatment.
- Understanding prognostic biomarkers is crucial for optimizing SCLC patient management.
Purpose of the Study:
- To explore the prognostic value of blood immune cell signatures in SCLC patients.
- To compare immune cell profiles between SCLC and non-small cell lung cancer (NSCLC) patients.
- To identify potential blood-based biomarkers for predicting SCLC patient survival.
Main Methods:
- Prospective observational study of 40 SCLC patients treated with chemotherapy and immune checkpoint inhibitors.
- Multi-color flow cytometry analysis of blood immune cells (neutrophils, T, B, NK cells, monocytes, dendritic cells) at baseline and cycle 3.
- Survival analysis (Overall Survival - OS) and comparison of immune parameters between SCLC and NSCLC cohorts.
Main Results:
- Disease progression correlated with higher neutrophil/lymphocyte ratio (NLR), more HLA-DRlow monocytes, and lower NK cells/dendritic cells (DCs).
- Risk factors for poor OS included brain/liver metastases, high baseline NLR (≥ 6.1), high HLA-DRlow monocytes (≥ 21%), low slan+ non-classical monocytes (< 0.12%), and low CD1c+ myeloid DCs (< 0.05%).
- SCLC patients exhibited higher rates of metastases, higher NLR, and lower DC/NK cell counts compared to NSCLC patients.
Conclusions:
- Blood immune cell signatures, particularly NLR, HLA-DRlow monocytes, and slan+ non-classical monocytes, are associated with poor survival in SCLC.
- Brain/liver metastases significantly impact SCLC patient survival.
- Immune cell profiling may enhance prognostic prediction and elucidate SCLC pathophysiology.
